Global Arthritis Drug Market Size By Type (Synthetic DMARDs, Biological DMARDs), By Application (Retail Pharmacies, Hospital Pharmacies), By Region, And Segment Forecasts, 2023 to 2032

The Global Arthritis Drug Market was valued at USD 52.3 billion in 2023 and is projected to surpass USD 85.7 billion by 2031, growing at a CAGR of 6.5% from 2023 to 2031. This growth is primarily driven by the rising prevalence of arthritis worldwide, the growing elderly population, increased access to advanced therapeutics, and the continual development of disease-modifying antirheumatic drugs (DMARDs) and biologics. Innovations in targeted drug delivery, coupled with improved healthcare infrastructure in emerging economies, are further fueling market expansion.

Drivers:

1. Rising Global Prevalence of Arthritis

With over 350 million people affected by arthritis globally, the demand for effective therapeutic solutions is surging. Osteoarthritis and rheumatoid arthritis remain the most common forms, and their growing incidence is a significant driver for the arthritis drug market.

2. Advancements in Biologic Therapies and DMARDs

The evolution of biologics, including TNF inhibitors and interleukin blockers, has revolutionized arthritis treatment, offering more targeted and effective management options. Continuous innovation in this space is propelling market growth.

3. Increasing Geriatric Population

Aging is a major risk factor for arthritis. The rising elderly demographic, particularly in developed nations, is contributing to the sustained demand for arthritis drugs.

Restraints:

1. High Cost of Biologics and Targeted Therapies

Advanced arthritis medications, especially biologics, are often expensive and may not be accessible to all patients, particularly in low- and middle-income countries, hindering broader market penetration.

2. Side Effects and Safety Concerns

Long-term use of certain arthritis drugs may lead to adverse effects, including gastrointestinal issues, liver damage, and increased infection risk. These safety concerns may deter adoption in some patient segments.

Opportunity:

1. Emerging Markets and Personalized Medicine

The arthritis drug market is poised for robust expansion in Asia-Pacific, Latin America, and the Middle East due to growing healthcare investments, rising disease awareness, and improving drug accessibility. Moreover, the integration of pharmacogenomics in treatment planning paves the way for personalized medicine in arthritis care.

Market by System Type Insights:

Biologic Response Modifiers (BRMs) dominated the system type segment in 2023, owing to their precision in targeting specific immune pathways. These include TNF inhibitors, IL-6 inhibitors, and JAK inhibitors. Their ability to halt disease progression and improve patient outcomes is driving preference over traditional NSAIDs and corticosteroids.

Market by End-use Insights:

Hospital Pharmacies accounted for the largest share of the market in 2023. The complexity of biologic administration and the need for professional supervision have kept hospital-based distribution dominant. However, retail pharmacies and online channels are projected to grow rapidly due to enhanced patient convenience and expanding e-pharmacy platforms.

Market by Regional Insights:

North America led the market in 2023, attributed to high arthritis prevalence, favorable reimbursement policies, and strong presence of key pharmaceutical companies. However, Asia-Pacific is anticipated to witness the highest CAGR during the forecast period due to increasing healthcare expenditure, aging population, and growing adoption of biologics in countries like China, India, and Japan.

Competitive Scenario:

Key players in the Global Arthritis Drug Market include AbbVie Inc., Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb, Amgen Inc., Eli Lilly and Company, Novartis AG, Roche Holding AG, Merck & Co., Inc., and Sanofi S.A. These companies are actively engaging in R&D activities, regulatory approvals, and strategic collaborations.

In 2023, AbbVie launched a next-generation JAK inhibitor for rheumatoid arthritis with improved safety profiles.

In 2024, Pfizer expanded its biosimilar portfolio targeting TNF-α inhibitors.

In 2025, Eli Lilly announced a new oral biologic therapy entering Phase III trials for osteoarthritis.

Scope of Work – Global Arthritis Drug Market

Key Market Developments:

2023: AbbVie launched Rinvoq® (upadacitinib) for psoriatic arthritis in several global markets.

2024: Amgen and Novartis expanded their strategic partnership to co-develop dual-action biologics.

2025: Johnson & Johnson gained FDA approval for its biosimilar version of etanercept, increasing access and affordability.

FAQs:

What is the current market size of the Global Arthritis Drug Market?

The Global Arthritis Drug Market was valued at USD 52.3 billion in 2023.

What is the major growth driver of the Global Arthritis Drug Market?

The major driver is the increasing prevalence of arthritis globally and innovations in biologic therapies.

Which is the largest region during the forecast period in the Global Arthritis Drug Market?

North America currently holds the largest market share, though Asia-Pacific is the fastest-growing.

Which segment accounted for the largest market share in Global Arthritis Drug Market?

Biologic Response Modifiers (BRMs) held the largest share by system type in 2023.

Who are the key market players in the Global Arthritis Drug Market?

Key players include AbbVie Inc., Pfizer Inc., Johnson & Johnson, Amgen Inc., Eli Lilly and Company, and Novartis AG.